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Abstract
Liver disease is an important clinical problem, impacting over 30 million Americans and over 600
million people worldwide. It is the 12th leading cause of death in the United States and the 16th
worldwide. Due to a paucity of donor organs, several thousand Americans die yearly while
waiting for liver transplantation. Unfortunately, alternative tissue sources such as fetal hepatocytes
and hepatic cell lines are unreliable, difficult to reproduce, and do not fully recapitulate hepatocyte
phenotype and function. As a consequence, alternative cell sources that do not have these
limitations have been sought. Human embryonic stem (hES) cell- and induced pluripotent stem
(iPS) cell-derived hepatocyte-like cells may enable cell based therapeutics, the study of the
mechanisms of human disease and human development, and provide a platform for pharmacology
and toxicology drug screening. iPS cells can be differentiated in a stepwise fashion with high
efficiency and reproducibility into hepatocyte-like cells that exhibit morphologic and phenotypic
characteristics of hepatocytes. In addition, iPS-derived hepatocyte-like cells possess some
functional hepatic activity as they secrete urea, alpha-1-antitrypsin, and albumin. However, the
combined phenotypic and functional traits exhibited by iPS-derived hepatocyte-like cells resemble
a relatively immature hepatic phenotype that more closely resembles that of fetal hepatocytes
rather than adult hepatocytes. Specifically, iPS-derived hepatocyte-like cells express fetal markers
such as alpha fetoprotein and lack key mature hepatocyte functions, as reflected by drastically
reduced activity (0.1%) of many detoxification enzymes (i.e. CYP2A6, CYP3A4). These key
differences between iPS-derived hepatocyte-like cells and adult hepatocytes have limited the use
of stem cells as a renewable source of functional adult human hepatocytes for in vitro and in vivo
applications. Unfortunately, the developmental pathways that control hepatocyte maturation from
a fetal into an adult hepatocyte are poorly understood, which has hampered the field in its efforts
to induce further maturation of iPS-derived hepatic lineage cells. This review analyzes recent
developments in the derivation of hepatocyte-like cells, and proposes important points to consider
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and assays to perform during their characterization. In the future, we envision that iPS-derived
hepatocyte-like cells will be used as in vitro models of human disease, and in the longer term,
provide an alternative cell source for drug testing and clinical therapy.
INTRODUCTION
Chronic liver disease is a significant cause of morbidity and mortality, impacting over 600
million people worldwide [1]. As a result, the number of people living with end stage liver
disease is increasing, and over 1 million people die each year from acute and chronic liver
disease across the globe [1]. Liver transplantation is currently the only definitive and
curative treatment for acute and chronic liver failure [2]. First accomplished in 1967 by
Thomas Starzl, liver transplantation has been an unquestioned clinical success; however, the
demand for liver transplantation has significantly outstripped the supply of donor organs
[2-4]. As a consequence, multiple attempts to expand the availability of donor organs have
been employed: opt-out organ donation programs, the use of suboptimal donor organs
(deceased cardiac donors or steatotic (fatty) livers), split donor transplantation, and living
donor liver transplantation [4].
The search for alternatives to whole organ transplantation has been focused on expanding
the availability of replacement liver tissue, such as developing cell-based therapies that
include hepatocyte transplantation, engineered hepatic tissue constructs, and the bioartificial
liver [5-9]. In particular, hepatocyte transplantation has been performed clinically for more
than 15 years, primarily in the setting of acute liver failure and inherited liver metabolic
disorders. A general problem facing hepatocyte transplantation is the limited repopulation
capacity of engrafted cells, although in the case of some metabolic disorders, replacement of
just 2–5% of the liver parenchyma with normal hepatocytes may be sufficient to improve
liver function significantly. For example, Fox et al reported the successful treatment of a 10-
year-old with one such metabolic disorder, termed Crigler–Najjar disease, who was
experiencing recurrent episodes of brain injury resulting from elevated bilirubin. The patient
was shown to respond well to infusion of 7.5×109 hepatocytes, based on an improvement in
metabolic function and reduced need for phototherapy [7]. However, hepatocyte
transplantation has not been widely adopted, due to a variety of technical reasons including
the inability to monitor graft health and frequent signs of rejection [8]. Moreover, these
clinical treatments require human liver tissue as a cell source of the transplanted hepatocytes
which, as mentioned, is in very short supply.
Based on the apparent success of hepatocyte transplantation combined with the challenges in
sourcing appropriate donor cells, a strong focus has been placed on developing a safe and
reliable method to expand the small number of available human hepatocytes. Indeed, the
liver has been known for its capacity to regenerate since antiquity, as encapsulated in the
story of Prometheus. Modern studies have shown that in vivo, human hepatocytes are
capable of cellular proliferation based on the observed replacement of damaged hepatocytes
following injury, or even during the daily turnover of the liver [10]. However, in vitro,
researchers have been unable to induce and/or support the cellular proliferation of human
hepatocytes; rather, attempts to culture human hepatocytes have led to the loss of
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differentiated function rather than any increase in cell number [11-12]. Consequently,
attempts to expand adult human hepatocytes have been unsuccessful as a target approach to
achieving cellular therapy of the liver, and alternatives are under active investigation. Other
approaches include utilizing cell lines derived from hepatocellular carcinoma, or generated
through SV40 or Big T antigen transformation, both of which have enabled the expansion
and creation of in vitro model systems [13]. Regrettably, these cell lines poorly recapitulate
hepatocyte function, as cultured cells lose most of their differentiated function and acquire
genetic abnormalities.
Several alternative sources have been proposed as options to circumvent the limited supply
of human hepatocytes, including using human fetal tissue or even xenogeneic material, but
both paths have been sidelined due to a variety of ethical, sourcing, and safety issues [14].
While still prone to some ethical and safety challenges, pluripotent stem cell-based therapies
overcome many of the drawbacks that challenge other cell lines and fetal tissue, and thus are
considered by many as an ideal alternative source of human hepatocytes [15-16]. Human
pluripotent stem cells include embryonic stem (hES) cells, first isolated from human
blastocysts by James Thomson and colleagues [17], as well as the more recently described
induced pluripotent stem (iPS) cells first generated by Yamanaka and colleagues following
the forced expression of a panel of transcription factors in adult-derived cells [18-19]. These
cell lines are defined as pluripotent in that they can self-renew in culture, maintain genetic
stability, and differentiate into cell lineages of all three germ layers including endodermal
hepatocyte-like cells (HLCs) [17-19]. Importantly, iPS cells can be derived from adult tissue
in a reliable manner and have been shown to differentiate efficiently into hepatocyte-like
cells [18-21]. However, unlike relatively simple in vitro models designed to reproduce
embryonic differentiation, in vivo development advances through a much more complex,
structured and highly organized series of patterning and differentiation events in which cell-
extracellular matrix and cell-cell interactions are tightly controlled and play an important
role [22-25]. Consequently, the hepatocyte-like cells generated from pluripotent stem cells
in culture exhibit many morphologic and phenotypic characteristics of human hepatocytes.
However, the examination of their functional traits has been more limited, and many signs
suggest that only partial differentiation has been attained, as discussed below.
Despite the challenges inherent in performing developmental studies in an in vitro setting,
and the roadblocks that remain regarding the current capacity to treat patients with human
hepatocytes from any available derivation source, the importance of being able to develop
experimental models to study human disease states cannot be overstated. To date, many
genome-wide association screens (GWAS) have identified a variety of genetic variants
associated with human liver disease [26]. However, many of these variants represent novel
loci whose contribution to liver disease is entirely unknown. Linking GWAS findings to
biologic mechanisms has been an ongoing challenge in the genetics community. In most
studies, mouse models have been employed; however, the usefulness of mouse models is
unclear given its low-throughput nature and the physiologic and metabolic differences
between humans and rodents [27-28]. Similarly, zebrafish models have been employed as a
higher-throughput system to examine numerous genetic variants but given the significant
developmental, structural, physiologic, and metabolic differences between species, the value
of these models is less clear [29-30]. Consequently, cell culture systems have been
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employed, despite the observation that although no single cell type tested to date fully
recapitulates hepatocyte morphology, phenotype, and function [31-33]. In contrast, iPS cells
offer the potential to establish patient-specific cell types such as iHLCs, thus facilitating in
vitro modeling of rare diseases, and may one day enable personalized medicine [18-19].
When combined with the capacity to engineer genetic changes in established iPS lines [34],
patient-specific iPS cells and iHLCs can be utilized to study genetic variants identified in
GWAS studies, as well as a host of other monogenic alterations to assay their impact on
hepatocyte differentiation, phenotype and function [35]. For example, recent papers have
demonstrated that iHLCs can recapitulate the disease phenotype of alpha-1-antitrypsin
disease, familial hyperlipidemia, and Wilson’s disease, although the capacity to apply this
approach to study polygenic disorders remains to be seen [35-37]. And yet, in order to
maximize the potential use of iPS-derived liver cells either for studies of disease models and
treatment, or for eventual cell transplantation therapies, it is essential that efficient and
reproducible iHLC differentiation protocols are established.
Significant progress has been made over the past few years in the derivation of pluripotent
stem cell derived hepatocyte-like cells and consequently, a multitude of differing protocols
have been developed to generate iHLCs [20-21, 38-40]. Most of these protocols share
general themes regarding their approach to differentiation induction, however, specific
differences are apparent upon close examination of the individual methodologies.
In this review, we overview some of the most established and cited iHLC methods. We
stress the importance of detailed characterization of derived cell types, and that multiple
phenotypic and functional read outs are required in this effort. Based on an analysis of the
available literature, we provide a summary of assays that can be applied during the analysis
of iHLC populations, towards the goal of promoting a unified field and achieving a robust,
mature source of this very important and clinically relevant lineage.
RESULTS AND DISCUSSION
For decades, researchers have been attempting to promote the in vitro differentiation of
primitive, and now pluripotent, cells towards specific lineages of all three germ layers. A
typical approach to designing such protocols has been to mimic the patterns and stages
observed during embryologic development, in order to recreate the necessary molecular and
cellular cues. In the case of pluripotent cells, most protocols apply either one of several
cellular aggregation strategies or promote differentiation in a monolayer culture. Pluripotent
stem cells can be aggregated in suspension or using specialized plates, which results in the
formation of three-dimensional structures called embryoid bodies (EBs) that may serve to
replicate some of the cell-cell and cell-matrix signals that are experienced during
development in vivo [41]. By culturing EBs in specific cytokine cocktails or on different
extracellular matrices - again, designed in an effort to mimic signals observed during
embryonic liver development - it is possible to improve the efficiency of pluripotent stem
cell-derived HLC generation [42]. However, all existing protocols still suffer from relatively
low differentiation efficiency, and tend to lead to the production of a variety of alternate cell
lineages, likely because EBs develop regional differentiation over time in what appears to be
a stochastic and spontaneous process. As a result, cultures that utilize an embryoid body step
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typically introduce an unpredictable degree of variability between differentiation attempts.
To address this problem, several groups have either switched to a monolayer-style culture
(often co-culture), and/or use hepatocyte reporter constructs that are only turned on at
specific stages of development, or sort desired populations based on the expression of cell
surface markers that are upregulated during the course of differentiation [43-44]. Using
these protocols, relatively pure subpopulations of cells can be isolated, and which have been
tested functionally in a variety of hepatocyte transplantation assays. Unfortunately, the
outcome of these experiments has varied widely, and to date, no papers have demonstrated
the ability to re-plate and use these cells in vitro [43].
More recently, several groups have optimized the differentiation procedure and eliminated
the use of poorly defined components such as serum, fibroblast feeder cells, embryoid
bodies, and other undefined culture medium components, and have optimized their protocols
based on a growing understanding of mouse hepatic development. These next generation
protocols typically start with pluripotent stem cells and in a stepwise manner, expose the
cultured cells to a series of defined factors in order to obtain iHLCs [18-21]. According to
these methods, iHLCs are obtained with a much higher efficiency than earlier aggregation
protocols, although scaleability remains a challenge in light of the numbers of cells that may
be required for future applications. The key to the success of these protocols was the ability
to promote the pluripotent cells to adopt a definitive endoderm fate at high efficiency. First
described in 2006 using embryonic stem cells, this class of protocols identified the role that
activin A and WNT3 signaling play during the establishment of the early primitive streak,
and that ultimately lead to endoderm specification [45-46]. These insights opened the door
to further refinements in the methodology, and enabled the derivation of visceral,
endodermal-derived tissues. These updated protocols yield hepatic lineage cells that can be
considered hepatic-like based on morphologic and some phenotypic analyses [20-21, 38].
However, functional and other specific phenotypic analyses demonstrate that the resulting
iHLCs exhibit an immature hepatic phenotype, in that they resemble fetal hepatocytes more
than adult hepatocytes. Notably, iHLCs persistently express fetal markers like alpha
fetoprotein (AFP) and lack key mature hepatocyte functions, as reflected by drastically
reduced activity (0.1%) of many detoxification enzymes (e.g. CYP2A6, CYP3A4) [20-21,
38]. These subtle but important differences between iHLCs and adult hepatocytes have
limited the use of stem cells as a renewable source of functional human hepatocytes.
Despite the development of multiple differentiation protocols it is unclear as to which
protocol leads to the production of the most terminally differentiated hepatocyte-like cells.
This challenge in comparison with adult-derived cells typically stems from the inclusion of
only minimally detailed functional analysis. Therefore, it is important to review the various
approaches that numerous labs use to validate the identity of the lineages and precursors that
result from hepatic differentiation methodologies. Indeed, in order to best optimize a
protocol designed to yield efficient, robust progeny of a desired lineage, it is essential that
appropriate functional tests are performed, and that reasonable control and ‘benchmark’
comparisons are made as part of the refining process. As an example, we have summarized
three differentiation protocols established by Si-Tayyeb et al, Song et al, and Touboul et al
[20-21, 38]. All protocols share a step-wise process to generate definitive endoderm,
followed by hepatic-specified endoderm, followed by hepatoblasts, and finally yield
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hepatocytes, although the precise culture conditions, growth factor combinations, kinetics,
efficiency, and overall protocol complexity vary in each case (Figure 1). In terms of the
reported characterization of the cells generated during the course of the procedures, Si-
Tayyeb et al completed immunofluorescence analysis, periodic acid Schiff staining for
glycogen production, LDL uptake, albumin secretion, and in vivo transplantation. Song et al
completed immunofluorescence analysis, periodic acid Schiff staining for glycogen
production albumin production assay, urea metabolism assay, and CYP2B analysis. Touboul
et al completed immunofluorescence analysis, flow cytometry analysis, indocyanine green
assay, CYP3A5/CYP3A7 (fetal cytochrome P450) analysis and in vivo transplantation. All
three of these examples highlight that, particularly in the case of the hepatocyte lineage, no
single assay can conclusively confirm a hepatic identity in isolation. However, as illustrated
by these three publications, there are a multitude of morphologic, phenotypic, and functional
tests which can be combined to demonstrate with confidence that pluripotent stem cell-
derived HLCs are similar in quality and function to primary human hepatocytes. For the
purposes of this review, we will describe a panel of these assays below.
Cellular morphology
Pluripotent stem cell derived hepatocyte-like cells should be cuboidal or polygonal in
appearance and have enlarged nuclei with an increased cytoplasm to nucleus ratio. In
electron microscopy studies, abundant mitochondria, perioxisomes, lipid bodies, intact golgi
apparati, and rough endoplasmic reticulum should be present. In addition, abundant
microvilli and vesicles should be visible, and junctional complexes should be present on
either side of nearby hepatocytes, consistent with bile canalicular network formation.
Gene and protein expression
In addition to the overall morphology of the population, confirming lineage identity depends
on demonstrating the presence or absence of expression of particular genes and proteins.
Based on developmental studies in vivo, numerous expected molecular phenotypes have
been defined throughout the differentiation process as pluripotent cells transition to an adult
hepatocyte state.Table 1 outlines expected expression patterns for various stages along the
differentiation cascade. In terms of RNA expression analysis, the preferred methodology is
to use quantitiative real-time PCR (qRT-PCR) analysis of pluripotent stem cell-derived
HLCs compared to a high-quality human hepatocyte reference (see below). At each
differentiation step it is important to characterize and demonstrate the commitment or
specification to the specified lineage. Protein immunofluorescence or immunohistochemistry
staining should be performed to confirm qRT-PCR data as well as to help determine marker
co-expression. This per-cell assay also allows for an assessment of overall differentiation
efficiency within a given culture well or plate. Cell polarization, an essential feature of
functional hepatocytes, can also be examined in this manner, in that several proteins (BSEP,
MRP-2, G6P, and several others) should only be expressed on apical or basolateral
membranes. Finally, at least a selection of the imaging stains should be confirmed by
Western blot of bulk populations, to decrease possibility of off-target staining results.
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Functional characterization
Pluripotent stem cell-derived HLCs should exhibit functional characteristics of hepatocytes,
in addition to their morphologic and phenotypic traits. Hepatocytes are notable for their
wide variety of metabolic and other functional capacities, spanning over 500 classes of
functions such as energy metabolism, bile production, and synthetic or detoxification
functions, and thus to conclusively validate their identity, a series of in vitro assays can be
performed to demonstrate activity in a variety of organized functional categories (Tables
2-3).
In vitro cell culture may enable phenotypic and functional iHLC characterization across a
variety of individual parameters, however, a higher bar – and to some, a necessary bar to
reach - is to achieve in vivo engraftment and function, and in some cases, functional rescue.
In conducting these assays, there are three essential sets of decisions that must be
considered: choice of recipient model and route/dose of administered cells, evaluation
methods used to determine the kinetics and extent of donor cell engraftment, and specific
functional outcomes examined to assess both local and systemic functional output of the
engrafted cells. A variety of models are available, each with relative strengths and
weaknesses. Two immunodeficient, metabolic mutation mouse models have often been
utilized to assay for robust engraftment and repopulation of primary human hepatocytes
include Fah−/−/Rag2−/−/IL2rγ−/− or alb-uPA severe combined immunodeficient mice
[47-48]. These models offer benefits in that endogenous liver cells are compromised, and
thus minimal donor cell engraftment may lead to a measureable functional read out, and yet
– as with most animal models – there remain some questions as to the absolute relevance of
the outcome, and whether engraftment in this setting will directly correlate with function in
a human. Nonetheless, although no iHLC transplant studies to date have observed
significant repopulation with functional activity, small islands of stem cell derived
hepatocyte-like cells have been detected using these compromised hosts. Highlighting the
importance of selecting an appropriate host model for functional engraftment studies, a
recent report described very high levels of albumin-staining following the transplantation of
iHLCs in a mouse model that has been traditionally utilized for toxicity testing of candidate
drugs [49]. In this case the stem cell-derived donor cells did not carry any genetic or
functional advantage over the surviving host cells, but did appear to be selected to
repopulate the damaged liver. Unfortunately, the degree to which the local human albumin-
staining cells contributed to circulating human markers of functional hepatocyte integration
was extremely and surprisingly low, but this observation went largely undiscussed in the
original publication. Overall, the unusually high levels of engraftment are encouraging for
the field, but clearly additional work remains to be done to demonstrate fully functional
engraftment of iHLCs in an in vivo setting. Given these observations, some researchers have
begun to explore alternate animal models, including rodents. Indeed, one group has
presented data in oral presentations showing that radiation preconditioning of host rats can
enhance the engraftment of human hepatocytes and iHLCs. Consequently, it seems likely
that identifying the most amenable, but appropriate, host model is both a central challenge
and an active area of investigation in this field.
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Finally, in all of the assays utilized to characterize candidate iHLC populations, particularly
their functional traits, comparison with an appropriate reference cell type is critical.
Hepatocyte reference controls such as cell lines or immortalized hepatocytes have been used
extensively, and offer a reproducible benchmark population, however, these lines do not
exhibit appropriate, physiological levels of most hepatocyte-specific functions. Freshly
isolated or uncultured, cryopreserved primary human hepatocytes are generally considered
the ideal reference controls for this purpose. However, many functional tests require that
cells are cultured for periods of ours to days, and once maintained in traditional culture
systems the morphology, phenotype, and function of primary human hepatocytes all rapidly
decline. Several updated in vitro platforms have been developed to preserve hepatic
morphology, phenotype, and many functions of primary adult hepatocytes (ie. matrigel
overlay, collagen gel sandwich, micropatterned cocultured hepatocytes, and three-
dimensional aggregates) [50-54]. Of these culture systems, micropatterned cocultured
human hepatocytes have been shown to most faithfully recapitulate human hepatocyte
function with maintenance of hepatic morphology, phenotype and function for up to four
weeks [52]. Other alternatives include human liver tissue homeogenates, human liver
microsome isolation, and tissue sections that have been shown to faithfully recapitulate gene
expression, cytochrome P450 activity and hepatocyte phenotype, although these systems
cannot be used for dynamic studies. For many characterization assays that do not require
periods of culture, such as gene expression, one of these alternatives or uncultured primary
human hepatocytes offer the ideal ‘benchmark’. However, for other methods that require
sample collection or observation over time in culture, we encourage the use of platforms
such as the MPCC, or related assays, for benchmarking purposes.
Unfortunately, while dozens of published papers demonstrate HLC production from a
variety of cell types, including pluripotent stem cells, the criteria used to identify the
resulting hepatocyte-like cells has varied from report to report. Due to this lack of
standardization of what defines an HLC, it has been difficult to compare the relative success
of various protocols, and thus it is close to impossible to identify candidate method
modifications that may enhance iHLC production. As mentioned above, many groups have
benchmarked their iHLC populations against cultured primary human hepatocytes, which
contribute to the challenge in comparing results across platforms due to the variability in
most human hepatocyte culture systems. Furthermore, multiple publications have
established that unless specific culture model systems are employed, such as the
micropatterned coculture system, cultured hepatocytes rapidly lose their phenotype and the
majority of typical functions. Moreover, cultured human hepatocytes upregulate
inappropriate and often immature markers such as AFP. Consequently, any comparisons
made to these altered adult hepatocytes may make the candidate iHLCs appear more
strongly functional than they truly are. Indeed, examination of published accounts reveals
that many protocols lead to fetal hepatocyte-like cells, although in some cases the
characterization reported is not sufficient to determine the fetal versus mature nature of the
resulting HLCs. Given the seemingly fetal nature of iHLCs produced to date, it is apparent
that additional, careful modification of differentiation protocols will be required before the
potential of pluripotent stem cell-derived hepatocyte-like cells can be realized.
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Even after reaching a suitably characterized iHLC state, a remaining issue is the question of
the stability of their phenotype and function in long-term culture, similar to the alterations
observed in cultured adult hepatocytes [55]. Consequently a variety of strategies have been
undertaken to improve the hepatocyte-specific functions and survival of primary hepatocytes
in vitro. Numerous studies have focused on strategies that aim to recapitulate the normal
liver microenvironment and provide missing microenvironmental cues including soluble
factors [55-56], cell-matrix interactions [57-59], and heterotypic cell-cell interactions with
nonparenchymal cells [60-61]. Microfabrication approaches (semiconductor-driven
microtechnology tools which enable micrometer-scale control over cell adhesion, shape and
multi-cellular interactions) have been utilized to control tissue microarchitecture in order to
define the best cell-matrix interactions and to achieve an optimal balance of homotypic and
heterotypic cellular interactions to promote hepatocyte function [62-63]. These approaches
have culminated in photolithographic cell patterning techniques and robust hepatocyte
culture model systems which has been used extensively for drug development and pathogen
modeling. These approaches will be critical to improving the development and culture of
iHLCs and will not only improve the robustness of the iHLC system but will help untangle
the role that soluble factors, cell-matrix interactions and homotypic and heterotypic cell-cell
interactions play in hepatic development. Notably, this area of study has also raised the
possibility that the observed heterogeneity of cell types produced using current iHLC
differentiation protocols may actually required for robust iHLC differentiation. That is,
during the course of iHLC generation, differentiating progenitors may require signals
produced by other cell types developed in parallel. Thus, it may not be possible to achieve a
pure population of functional iHLCs, unless replacement signals and/or factors can be
defined and provided with appropriate kinetics. All of the above underscore the need for live
cell reporters that allow differentiation state to be monitored, and permit subsequent
isolation of desired populations.
The differentiation protocols currently used to coax pluripotent stem cells to generate
hepatocyte-like cells rely on the addition of exogenous growth factors identified in
developmental studies. Subsequent work has established the key transcription factors that
are activated during the course of the hepatic differentiation process. Other groups have
demonstrated that direct reprogramming strategies which bypass the pluripotent stage can be
applied to convert fibroblasts into cardiomyocytes and neurons by overexpressing key
lineage-specific transcriptional regulators. Motivated by these findings, two groups have
recently shown that mouse fibroblasts can be reprogrammed into hepatocyte-like cells via
the overexpression of key transcription factors (ie. Foxa2/3, HNF1α and GATA4 or
Foxa1/2/3 and HNF4α) [64-65]. In both examples, induced hepatocytes exhibited only
minimal hepatocyte-specific functions including very low albumin secretion, triglyceride
synthesis, and cytochrome P450 function. Transplantation of induced hepatocytes into FAH
deficient mice (a genetic model of hereditary tyrosinemia that develops liver failure without
NTBC drug treatment) led to liver repopulation and survival of less than half of the hosts.
This partial success stands in contrast to reported outcomes using primary mouse
hepatocytes which repopulate the complete liver with rare failure to rescue the mice from
death. Whether these differences in repopulation and in vitro hepatic function reflect
variable reprogramming, dysregulated function or immature cells is still unclear.
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iPS and iHLCs offer a dizzying array of opportunities including hepatocyte-like cell
generation for possible cell replacement therapy. However, this noble goal is likely still far
on the horizon, and thus their greatest strength, or at least the most near-term potential of
iHLCs, may lie in applying them to serve as a platform for disease modeling, or for
mechanistic toxicity studies in idiosyncratic responses. The cost of drug development is
heavily influenced by the attrition rate of tested compounds; for every drug that reaches the
marketplace, 5,000 to 10,000 molecules were tested preclinically [66]. Utilizing iHLCs for
this sort of application will require an experimental platform that is robust and scaleable, and
that involves multiple essential steps. First, a target disease that exhibits a recognizable in
vitro phenotype must be selected, and candidate tissue donors with the target disease need to
be identified, as well as healthy control subjects. Second, iPS cells need to be derived,
characterized, and grown in an easily scaleable platform. Third, differentiation of iPS cells
into iHLCs needs to be efficient, complete, consistent, and conducted in a format
appropriate for large-scale small molecule testing (ie. at least 96, 384, or 1024 wells). While,
as discussed above, current best-available iHLCs remain incompletely differentiated, reports
of the successful application of this process have been described for patients with alpha-1-
antitrypsin disease and familial hyperlipidemia [35-36]. However, in the case of polygenic,
and thus genetically complex diseases such as nonalcoholic fatty liver disease, screening for
a specific phenotypic or functional outcome may not be possible, even after new methods
have been developed to achieve more complete and robust stem cell-derived hepatocyte
production. Consequently, no matter what disease is being interrogated, a differentiation
platform designed for screening or modeling must produce pure populations of fully
differentiated cells with minimal heterogeneity and with no stochasticity. Certainly, further
improvements currently under examination by the stem cell and engineering communities
such as efforts to identify microenvironmental signals to increase the purity, efficiency and
maturation of desired cell types are likely to help tackle and solve these various problems.
iHLCs can also enable studies of pathogens that exclusively target human hepatocytes,
notably those with profound global health implications such as hepatitis B virus (HBV),
hepatitis C virus (HCV) and malaria. For example, current HCV model systems utilize the
Huh7 hepatoma carcinoma cell line to examine the HCV viral life cycle in vitro which is
limited by the poor hepatic function of the line [67-68]. Consequently, recent approaches
using micropatterning techniques have enabled HCV infection in primary human
hepatocytes [69]. More recently, we demonstrated that iHLCs express all known entry
factors of HCV, support the complete HCV viral cycle, and exhibit a robust anti-viral
immune reponse [70]. iHLCs can thus serve as a platform to explore the role that host
genetics plays in viral pathogenesis and elucidate the role that these host factors plays in
disease pathogenesis.
CONCLUSIONS
In summary, pluripotent stem cell derived hepatocyte-like cells can be generated from iPS
cells and hESC in a reproducible and efficient manner. Review of several available methods
reveal that there are multiple paths that lead from pluripotency to at least an immature
hepatic phenotype that more closely resembles fetal rather than adult hepatocytes. This
apparent incomplete differentiation state likely results from our poor understanding of the
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mechanisms underlying the developmental shift from fetal to adult liver. Moreover, the
existing lack of standardization of morphologic, phenotypic, and functional characterization
of iHLCs has made comparisons between published papers challenging, if not impossible. In
this review, we have illustrated the importance of extensive phenotypic and functional
characterization and we encourage the community to apply various standards during
hepatocyte-like cell characterization. In addition, the use of well-documented and functional
hepatocyte reference controls is key to the future improvement of iHLC generation. This
advance will lead to the rapid adoption of this key population and their use in a variety of
applications including the study of the mechanisms of human disease and development, and,
perhaps in the longer term, as a platform for pharmacology and toxicology drug screening
and cell based therapeutics.
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Figure 1. Generation of hepatocyte-like cells from iPS cells via three stepwise protocols
Schematic outlining the differentiation kinetics and growth factors utilized in three different
but commonly used protocols established by Si-Tayyeb et al, Song et al, and Touboul et al
[20-21, 38].
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Table 1
Marker expression throughout hepatocyte differentiation
Gene iPS DefinitiveEndoderm
Hepatic
Specified
Hepatoblast
specification
Fetal
Hepatocyte
Adult
Hepatocyte
Endoderm
OCT3/4 + − − NT NT +
Nanog + − − NT NT −
SSEA4 + − − NT NT −
TRA1-60 + − − NT NT −
FOXA2 − + +,lower + + +
GATA-4 − + +,lower + + +
Cereberus − + − − − −
FGF17 − + − − − −
Goosecoid − + − − − −
HNF4α −
− 
* + + + +
hHex − + +,very low − − −
MixL1 − + − − − −
Sox7 −
-
*
− − − −
Sox17 − + +,lower +,lower +,lower +,very low
APOA1 − − + + + +
APOB − − + + + +
BMP6 − − + − − −
DUSP6 − − + − − −
TBX3 − − + + + +
AFP − − − + + −
Decorin − − − + + +
HNF1α − − − + + +
GSTA1 − − − + + +
KRT19 − − − + +/− −
TTR − − − + + +
α1AT − − − − + +
Albumin − − − +/− + +
ASGPR1 − − − − − +
CPS1 − − − − − +
CK8 − − − − + +
CK18 − − − − + +
CYP1A2 − − − − − +
CYP2A6 − − − − − +
CYP2B6 − − − − − +
CYP2C9 − − − − − +
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Gene iPS DefinitiveEndoderm
Hepatic
Specified
Hepatoblast
specification
Fetal
Hepatocyte
Adult
Hepatocyte
Endoderm
CYP2C19 − − − − − +
CYP2D6 − − − − − +
CYP3A4 − − − − − +
CYP3A7 − − − − + very low
MAOA/B − − − − very low +
UGT1A1 − − − − − +
MRP2 − − − − very low +
BSEP − − − − very low +
*
Expression of Sox7 or HNF4α at the definitive endoderm stage indicates production of embryonic rather than definitive endoderm
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Table 2
Characteristic Functional Traits in both Fetal and Adult Hepatocytes
Fetal Hepatocyte Adult Hepatocyte
Synthetic Function
 AFP Production [71] + −
 Albumin Production [42] + +
 Alpha-1-Antitrypsin Production [9] + +
Energy Metabolism
  Lipid Metabolism
 LDL-R Expression [35] + +
 LDL Uptake [35] + +
  Glucose Metabolism
 Glucose Synthesis [72] + +
 Glycogen Production [20] + +
 Glucose-6-Phosphatase Activity [72] + +
  Protein Metabolism + +
 Ammonia Uptake/Urea Production [9] + +
Bile Production and Metabolism
 Production and Secretion of bilirubin
 monoglucuronide and diglucuronide [73]
NT +
 Uptake of bile acids and secretion into hepatic
 biliary canalicular networks [74]
+ +
Detoxification
  Cytochrome P450 Function
 CYP1A2 [52] − +
 CYP2A6 [52] − +
 CYP3A4 [52] − +
 CYP3A4/CYP3A7 + + (same as CYP3A4)
  Drug Metabolism Assays
 Buproprion [52] NT +
 Testosterone [52] NT +
  Drug Induction Assays
 Omeprazole (CYP1A2, CYP2B6, CYP3A4) [52] − +
 Rifampin (CYP2A6, CYP2B6, CYP3A4) [52] − +
 Β-Naphthloflavone (CYP1A2, CYP2B6) [52] NT +
 Phenobarbital (CYP2A6, CYP2B6, CYP3A4) [52] NT +
  Drug Metabolism Assays
 Buproprion [52] NT +
 Testosterone [52] NT +
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Table 3
Example functional assays with expected outcomes using adult hepatocytes
Assay name Assay format Specific examples
Cytochrome
P450 induction
Pretreatment of cells with a variety
of known cytochrome P450 inducers
• β-naphtholflavone (CYP1A, CYP2A6, CYP2B6)
• omeprazole (CYP1A, CYP2A6, CYP2B6, CYP3A4)
• phenobarbital (CYP2A6, CYP2B6, CYP3A4)
• rifampin (CYP2A6, CYP2B6, CYP3A4)
Drug toxicity Known hepatotoxins lead to
measurable TC50 via MTT or
mitochondrial activity assays
• chlorporamazine
• troglitazone
• tolcapone
• rifampin
Drug inhibition Evaluate drugs that lead to dose-
dependent inhibition of cytochrome
P450 function
• methoxsalen (CYP2A6)
• sulfaphenazole (CYP2C9)
• probenacid (glucoronidation)
Drug-Drug
interaction
Evaluate for drug-mediated
modulation of cytochrome P450
expression that result in altered
toxicity of combined drug
• phenobarbitol or rifampin pretreatment followed by acetaminophen
dosing leads to increased toxicity
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